<DOC>
	<DOCNO>NCT01128153</DOCNO>
	<brief_summary>The purpose study determine whether addition saxagliptin patient 's combination treatment metformin sulfonylurea 24 week period provide good control patient 's type 2 diabetes well tolerate .</brief_summary>
	<brief_title>Saxagliptin Triple Oral Therapy</brief_title>
	<detailed_description>A 24-week , Multicentre , Randomised , Double-Blind , Placebo-Controlled Phase IIIb Study Evaluate Efficacy Safety Saxagliptin Combination Metformin Sulfonylurea Subjects Type 2 Diabetes Inadequate Glycaemic Control Combination Metformin Sulfonylurea</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Written Informed Consent Males females type 2 diabetes inadequate glycaemic control ( HbA1c &gt; = 7 % &lt; = 10 % ) despite combination metformin sulfonylurea least 8 week prior Visit 1 BMI &lt; = 40 kg/m2 Symptoms poorly control diabetes include limited mark polyuria mark polydipsia &gt; 10 % weight loss 3 month prior entry , sign symptoms History diabetic ketoacidosis hyperosmolar nonketotic coma Current prior use within 3 month Visit 1 insulin , DDP4 inhibitor , GLP1 analogues , and/or oral antidiabetic agent ( metformin sulfonylurea ) Treatment CYP3A4 inducer and/or potent CYP3A4/5 inhibitor Estimated CrCl &lt; 60 ml/min Visit 2 CHF ( NYHA class III IV ) and/or LVEF &lt; 40 % Active liver disease and/or significant abnormal liver function define AST and/or ALT &gt; 3 x ULN and/or bilirubin &gt; 2.0 mg/dL Visit 2 . Creatine kinase &gt; = 10 x ULN Visit 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Inadequate Glycaemic Control</keyword>
	<keyword>Saxagliptin</keyword>
	<keyword>Metformin</keyword>
	<keyword>Sulfonylurea</keyword>
	<keyword>Triple Oral Therapy</keyword>
</DOC>